Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 12/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562791 | 1.00 | PRMT3 (0.52) | PRMT3ROCK1ROCK2CCNE1CDK2 | |
| SCHEMBL1124139 | 0.99 | PRMT3 (0.51) | PRMT3ROCK1ROCK2CCNE1CDK2 | |
| SCHEMBL13302852 | 0.95 | PRMT3 (0.47) | PRMT3ROCK1ROCK2CCNE1CDK2 | |
| SCHEMBL13302851 | 0.94 | PRMT3 (0.46) | PRMT3ROCK1ROCK2CCNE1CDK2 | |
| SCHEMBL13764335 | 0.87 | ROCK2 (0.60) | PRMT3ROCK1ROCK2IMPDH2 | |
| SCHEMBL13764333 | 0.85 | ROCK2 (0.61) | PRMT3ROCK1ROCK2IMPDH2 | |
| SCHEMBL1123677 | 0.82 | ROCK2 (0.54) | PRMT3ROCK1ROCK2 | |
| SCHEMBL14562668 | 0.82 | ROCK2 (0.54) | PRMT3ROCK1ROCK2 | |
| SCHEMBL14562581 | 0.81 | ROCK2 (0.55) | PRMT3ROCK1ROCK2 | |
| SCHEMBL1123536 | 0.81 | ROCK2 (0.55) | PRMT3ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2546239-B1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2546239-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546237-A1 | 7-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546239-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546238-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8153654-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009091898-A2 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | COQ8A, MAP3K7, PRKG2 | PRMT3 657/4885ROCK1 304/4885ROCK2 214/4885 |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | COQ8A, MAP3K7, PRKG2 | PRMT3 657/4885ROCK1 304/4885ROCK2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.